Seegene's gastrointestinal tract infection test product, evaluate to be superior to the culture method or the diagnosis using a microscope
Apr 14, 2019
Seegene's presentation on the clinical results on effectiveness of the meningitis infection products and gastrointestinal tract infection tests ("GI products") was very well-received at the 29th ECCMID symposium, held in Amsterdam RAI Exhibition and Convention Centre.
According to the WHO investigation, the gastrointestinal tract infections such as food poisoning that accompanies diarrhea may be caused by bacteria, viruses, and/or parasites. Every year, 3 to 5 billion patients suffer from these infections and 2 million die from them across the globe, and infants and children, in particular, have a 40% mortality rate. However, existing diagnosis methods for gastrointestinal tract infections have their limitations such as narrow coverage of causative pathogens and long turn-around-time. Seegene's GI products can test 99% of the causative pathogens at the same time and enables same-day diagnosis. This is why they attract a lot of attention from the field every year.
Seegene's GI products have received attention from the academia after the symposium in 2017 for its 'combination testing' and efficiencies. The launch of the new products, Allplex™ GI-Helminth (I) Assay that can test 9 types of protozoa and helminths which are highly pathogenic parasites and two other products, has brought even more attention of the academia and the industry.
At this year's symposium, the world-famous scholars, Dr. Alexander Dalpke of Germany, Dr. Andrea Boggild of Canada, and Dr. Hanne Holt of Denmark gave a presentation respectively under the theme of 'Uncovering the potential of infection diseases: One time, Right results', introducing the clinical results in comparison with gold standard diagnosis methods. The scholars gave in-depth presentations on efficiencies of Seegene's GI products that showed a significant difference in accuracy and testing time compared to the conventional method as well as the difference in result as an alternative testing method and its clinical effectiveness. They emphasized its convenience of reducing manual work in the laboratory and also introduced the performance of the newly launched products.
Meanwhile, Dr. Catherine Moore and Laura Gifford of UK ended the symposium with a presentation on the clinical results of using the Seegene’s meningitis test product for CSF, blood samples of patients. Suggesting it as the most efficient method for the syndromic test, the hottest trend in the diagnosis market, the scholars presented the optimized product for high volume of tests with convenience of automated system.
This year's ECCMID symposium started on April 13th and was held for 4 days with participation of 13,000 European clinical microbiologists and infectious disease experts.